COMPARISON OF HUMAN IMMUNE-RESPONSES TO PURIFIED VERO CELL AND HUMAN-DIPLOID CELL RABIES VACCINES BY USING 2 DIFFERENT ANTIBODY TITRATION METHODS
COMPARISON OF HUMAN IMMUNE-RESPONSES TO PURIFIED VERO CELL AND HUMAN-DIPLOID CELL RABIES VACCINES BY USING 2 DIFFERENT ANTIBODY TITRATION METHODS
复制标题
DOI：
10.1128/jcm.28.8.1847-1850.1990
复制
发表时间：
1990-08-01
影响因子：
9.4
通讯作者：
OLSVIK, O
中科院分区：
文献类型：
--
作者：
KITALA, PM;LINDQVIST, KJ;OLSVIK, O
在 80 名健康的肯尼亚兽医学生中比较了新型纯化 Vero 细胞狂犬病疫苗 (PVRV) 和人二倍体细胞疫苗 (HDCV) 对传统狂犬病暴露前方案的抗体反应。其中 43 名学生在第 0、7 和 28 天接种了 PVRV，37 名学生接种了 HDCV。在第 0、7、28 和 49 天使用快速荧光聚焦抑制试验 (RFFIT) 和抑制酶免疫测定 (INH EIA) 监测抗体反应。两种疫苗均引发了快速抗体反应。 RFFIT 滴度和 INH EIA 滴度之间具有良好的相关性 (r = 0.90)。我们的结果还表明，INH EIA 更具可重复性，因此可能是更昂贵且可重复性较差的 FFIT 的合适替代品。测试期间，两组学生的几何平均滴度在统计上相似。 RFFIT 和 INH EIA 给出了相当的几何平均滴度，仅在 PVRV 组的第 28 天存在显着差异。根据现有测试系统的测定，新型 PVRV 的效果与更昂贵的 HDCV 相当。因此，PVRV 可能是首选疫苗，特别是在热带狂犬病流行地区，HDCV 的高成本限制了少数特权人士的使用。
Antibody responses to a conventional rabies preexposure regimen of a new purified Vero cell rabies vaccine (PVRV) and a human diploid cell vaccine (HDCV) were compared in 80 healthy Kenyan veterinary students. Forty-three of the students received the PVRV and 37 received the HDCV on days 0, 7, and 28. Antibody responses were monitored by using the rapid fluorescent-focus inhibition test (RFFIT) and an inhibition enzyme immunoassay (INH EIA) on days 0, 7, 28, and 49. Both vaccines elicited a rapid antibody response. A good correlation between the RFFIT titers and the INH EIA titers were obtained (r = 0.90). Our results also showed that the INH EIA was more reproducible and might therefore be a suitable substitute for the more expensive and less reproducible FFIT. The geometric mean titers determined by both tests in the two groups of students were statistically similar during the test period. The RFFIT and INH EIA gave comparable geometric mean titers, which differed significantly only on day 28 in the PVRV group. The effect of the new PVRV is comparable to that of the more expensive HDCV, as determined by the present test systems. The PVRV could therefore be the vaccine of choice, especially in tropical rabies-endemic areas, where the high cost of the HDCV has confined its use ot a privileged few.